Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Effect of denosumab on bone mineral density in postmenopausal Japanese women with osteopenia receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e12536

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e12536)

Author(s): Katsuhiko Nakatsukasa, Takayuki Matsuda, Tetsuya Taguchi; Dept. of Endocrine & Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan; Saiseikai Kyoto Hospital, Kyoto, Japan

Abstract Disclosures

Abstract:

Background: Patients receiving aromatase inhibitor (AI) are at increased risk for bone fracture, which can reduce their quality of life. Efforts to prevent BMD loss are thus needed. Thus far, in Japan, the efficacy of denosumab in the treatment of AI-associated bone loss has not been evaluated in a prospective study. We previously reported the results of a 12-month, nonrandomized prospective study, which demonstrated that denosumab, a fully human monoclonal antibody against receptor activator of nuclear-factor kappa-B ligand (RANKL), increased the bone mineral Density (BMD) at the lumbar spine and femoral necks in patients with hormone receptor-positive breast cancer who were receiving adjuvant AI therapy and had evidence of low bone mass. Herein, we present the results of these therapeutic effects of 24-month denosumab therapy on the percentage change in BMD from baseline at the lumber spine and femoral necks. Methods: This non-randomized prospective study was conducted in Japan. we prospectively evaluated the BMD of the lumbar spine and bilateral femoral neck in hormone-receptor positive clinical stageⅠ–ⅢA, postoperative postmenopausal breast cancer patients who were scheduled for treatment with AI as adjuvant endocrine therapy or during AI adjuvant therapy. They received supplemental calcium, vitamin D and subcutaneous denosumab 60mg (n = 103) every six months. At enrollment, all patients were required to have evidence of low bone mass, excluding osteoporosis. The secondary endpoint was percentage change from baseline in lumbar spine BMD at 24 months. Results: We enrolled 103 patients between November, 2014 to October, 2016. At 24 months, lumber spine BMD increased by 7.0 %. The patients who were administered prior AI therapy (n = 62) had a 7.0 % increase, and the patients without prior AI therapy (n = 29) had a 6.8 % increase. At 24 months, the right and left femoral neck BMD increased by 3.4 % and 3.6 %. Conclusions: Twice-yearly treatment with denosumab was associated with consistently greater gains in BMD among Japanese women receiving adjuvant AI therapy, regardless of whether prior AI therapy was administered. Clinical trial information: UMIN000022256.

 
Other Abstracts in this Sub-Category:

 

1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...